Hjorth M - Search Results

1

Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. The Myeloma Group of Western Sweden.

Hjorth M, Hellquist L, Holmberg E, Magnusson B, Rödjer S, Westin J. Hjorth M, et al. Br J Haematol. 1990 Feb;74(2):185-91. doi: 10.1111/j.1365-2141.1990.tb02564.x. Br J Haematol. 1990. PMID: 2180471 Clinical Trial.

2

Impact of active and passive exclusions on the results of a clinical trial in multiple myeloma. The Myeloma Group of Western Sweden.

Hjorth M, Holmberg E, Rödjer S, Westin J. Hjorth M, et al. Br J Haematol. 1992 Jan;80(1):55-61. doi: 10.1111/j.1365-2141.1992.tb06400.x. Br J Haematol. 1992. PMID: 1536810 Clinical Trial.

3

Interferon therapy during the plateau phase of multiple myeloma: an update of the Swedish study.

Westin J, Cortelezzi A, Hjorth M, Rödjer S, Turesson I, Zador G. Westin J, et al. Among authors: hjorth m. Eur J Cancer. 1991;27 Suppl 4:S45-8. doi: 10.1016/0277-5379(91)90571-t. Eur J Cancer. 1991. PMID: 1799477 Clinical Trial.

4

Patient accrual and quality of participation in a multicentre study on myeloma: a comparison between major and minor participating centres.

Hjorth M, Holmberg E, Rödjer S, Taube A, Westin J. Hjorth M, et al. Br J Haematol. 1995 Sep;91(1):109-15. doi: 10.1111/j.1365-2141.1995.tb05254.x. Br J Haematol. 1995. PMID: 7577616 Clinical Trial.

5

Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Cooperative Study Group.

Westin J, Rödjer S, Turesson I, Cortelezzi A, Hjorth M, Zador G. Westin J, et al. Among authors: hjorth m. Br J Haematol. 1995 Mar;89(3):561-8. doi: 10.1111/j.1365-2141.1995.tb08364.x. Br J Haematol. 1995. PMID: 7734355 Clinical Trial.

6

Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I--a randomized study. Myeloma Group of Western Sweden.

Hjorth M, Hellquist L, Holmberg E, Magnusson B, Rödjer S, Westin J. Hjorth M, et al. Eur J Haematol. 1993 Feb;50(2):95-102. doi: 10.1111/j.1600-0609.1993.tb00148.x. Eur J Haematol. 1993. PMID: 8440364 Clinical Trial.

7

Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group.

Wisløff F, Eika S, Hippe E, Hjorth M, Holmberg E, Kaasa S, Palva I, Westin J. Wisløff F, et al. Among authors: hjorth m. Br J Haematol. 1996 Mar;92(3):604-13. doi: 10.1046/j.1365-2141.1996.352889.x. Br J Haematol. 1996. PMID: 8616024 Clinical Trial.

8

Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group.

Wisløff F, Hjorth M, Kaasa S, Westin J. Wisløff F, et al. Among authors: hjorth m. Br J Haematol. 1996 Aug;94(2):324-32. doi: 10.1046/j.1365-2141.1996.d01-1802.x. Br J Haematol. 1996. PMID: 8759893 Clinical Trial.

9

Survival in conventionally treated younger (<60 years) multiple myeloma patients: no improvement during two decades. Nordic Myeloma Study Group (NMSG).

Hjorth M, Holmberg E, Rödjer S, Turesson I, Westin J, Wislöff F. Hjorth M, et al. Eur J Haematol. 1999 Apr;62(4):271-7. doi: 10.1111/j.1600-0609.1999.tb01757.x. Eur J Haematol. 1999. PMID: 10227461 Clinical Trial.

10

[High-dose melphalan with stem cell support is now an established myeloma therapy. Treatment of myeloma from a 30-year perspective].

Hjorth M, Lenhoff S, Turesson I, Westin J. Hjorth M, et al. Lakartidningen. 2000 Oct 11;97(41):4585-6, 4589-92. Lakartidningen. 2000. PMID: 11107744 Clinical Trial. Swedish.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

217 results

Search Page

Filters